UroGen Pharma Statistics Share Statistics UroGen Pharma has 46.26M
shares outstanding. The number of shares has increased by 9.63%
in one year.
Shares Outstanding 46.26M Shares Change (YoY) 9.63% Shares Change (QoQ) 0.34% Owned by Institutions (%) 87.82% Shares Floating 37.03M Failed to Deliver (FTD) Shares 2,693 FTD / Avg. Volume 0.22%
Short Selling Information The latest short interest is 7.94M, so 17.17% of the outstanding
shares have been sold short.
Short Interest 7.94M Short % of Shares Out 17.17% Short % of Float 17.44% Short Ratio (days to cover) 5.89
Valuation Ratios The PE ratio is -3.6 and the forward
PE ratio is -21.99.
UroGen Pharma's PEG ratio is
0.22.
PE Ratio -3.6 Forward PE -21.99 PS Ratio 5.05 Forward PS 3 PB Ratio -51.87 P/FCF Ratio -4.7 PEG Ratio 0.22
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for UroGen Pharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.01,
with a Debt / Equity ratio of -14.02.
Current Ratio 6.01 Quick Ratio 5.81 Debt / Equity -14.02 Debt / EBITDA -1.12 Debt / FCF -1.27 Interest Coverage -7.73
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $386.32K Profits Per Employee $-542.2K Employee Count 234 Asset Turnover 0.32 Inventory Turnover 0.96
Taxes Income Tax 2.83M Effective Tax Rate -2.28%
Stock Price Statistics The stock price has increased by 37.88% in the
last 52 weeks. The beta is 1.02, so UroGen Pharma's
price volatility has been higher than the market average.
Beta 1.02 52-Week Price Change 37.88% 50-Day Moving Average 19 200-Day Moving Average 12.75 Relative Strength Index (RSI) 42.2 Average Volume (20 Days) 1,205,503
Income Statement In the last 12 months, UroGen Pharma had revenue of 90.4M
and earned -126.87M
in profits. Earnings per share was -2.96.
Revenue 90.4M Gross Profit 81.52M Operating Income -96.78M Net Income -126.87M EBITDA -110.33M EBIT -88.11M Earnings Per Share (EPS) -2.96
Full Income Statement Balance Sheet The company has 171.99M in cash and 123.39M in
debt, giving a net cash position of 48.6M.
Cash & Cash Equivalents 171.99M Total Debt 123.39M Net Cash 48.6M Retained Earnings -806.22M Total Assets 208.72M Working Capital 149.32M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -96.77M
and capital expenditures -295K, giving a free cash flow of -97.06M.
Operating Cash Flow -96.77M Capital Expenditures -295K Free Cash Flow -97.06M FCF Per Share -2.26
Full Cash Flow Statement Margins Gross margin is 90.18%, with operating and profit margins of -107.06% and -140.35%.
Gross Margin 90.18% Operating Margin -107.06% Pretax Margin -137.22% Profit Margin -140.35% EBITDA Margin -122.05% EBIT Margin -107.06% FCF Margin -107.37%
